Table 4.
Antithrombotic agents used in the CAA population before and after CAA diagnosis
| Before index date | After index date | |||
|---|---|---|---|---|
| 1 year | 3 month | 6 month | 1 year | |
| N (%) | N (%) | N (%) | N (%) | |
| Pediatric population (N = 586) | ||||
| Aspirin | 182 (31.1) | 479 (81.7) | 482 (82.3) | 486 (82.9) |
| Clopidogrel | 1 (0.2) | 4 (0.7) | 4 (0.7) | 4 (0.7) |
| Dipyridamole | 43 (7.3) | 95 (16.2) | 97 (16.6) | 99 (16.9) |
| Warfarin | 7 (1.2) | 25 (4.3) | 26 (4.4) | 27 (4.6) |
| Heparin | 5 (0.9) | 31 (5.3) | 33 (5.6) | 34 (5.8) |
| Adult population (N = 811) | ||||
| Aspirin | 575 (70.9) | 667 (82.2) | 678 (83.6) | 689 (85.0) |
| Clopidogrel | 256 (31.6) | 510 (62.9) | 514 (63.4) | 523 (64.5) |
| Dipyridamole | 127 (15.7) | 81 (10.0) | 94 (11.6) | 108 (13.3) |
| Ticlopidine | 32 (3.9) | 26 (3.2) | 31 (3.8) | 36 (4.4) |
| Tirofiban | 22 (2.7) | 28 (3.5) | 28 (3.5) | 29 (3.6) |
| Cilostazol | 20 (2.5) | 26 (3.2) | 29 (3.6) | 41 (5.1) |
| Warfarin | 60 (7.4) | 126 (15.5) | 132 (16.3) | 141 (17.4) |
| Heparin | 164 (20.2) | 551 (67.9) | 562 (69.3) | 577 (71.1) |
| Enoxaparin | 60 (7.4) | 131 (16.2) | 140 (17.3) | 147 (18.1) |